Global /Germany /Healthcare /Diagnostics & Research /MYNZ

Mainz Biomed N.V.

MYNZ

• NASDAQ: MYNZ • Delayed

0.4569USD -9%

As of 7 June 2026, Mainz Biomed N.V. has a market cap of $5.72M USD, ranking #43907 globally and #420 in Germany. It ranks #3895 in the Healthcare sector, and #16 in the Diagnostics & Research industry.

Global Rank

43907

Country Rank

420

Sector Rank

3895

Industry Rank

Key Stats

Market Cap

$5.72MUSD

Enterprise Value

$7.96MUSD

Revenue (TTM)

$537.08KUSD

EBITDA (TTM)

-$12.88MUSD

Net Income (TTM)

-$16.21MUSD

PS Ratio

11.7

PB Ratio

7.6

Company Profile

Country (HQ)

Germany

Sector

Healthcare

Industry

Diagnostics & Research

CEO

Guido Baechler open_in_new

Employees

Founded

2008

IPO

05 Nov 2021

Website

mainzbiomed.com open_in_new

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-9%	-16%	-0.2%	-63%	-72%	-61%	-88%	-100%	-100%

News

MYNZ Analyst Forecasts

Markets

Exchange	Ticker	Price	Quotes
NASDAQ MIC: XNAS PRIMARY	MYNZ Mainz Biomed NV ISIN: NL0015000LC2 Shares Out.: Shares Outstanding: 9.06M¹ Shares Float: 7.211M² TV: TradingView: NASDAQ: MYNZ SA: Stock Analysis: NASDAQ: MYNZ YF: Yahoo Finance: MYNZ GF: Google Finance: NASDAQ: MYNZ NQ: NASDAQ: MYNZ BA: Barron's: MYNZ MS: Morningstar: XNAS: MYNZ	0.4569 USD	TV: TradingView: NASDAQ: MYNZ SA: Stock Analysis: NASDAQ: MYNZ YF: Yahoo Finance: MYNZ GF: Google Finance: NASDAQ: MYNZ NQ: NASDAQ: MYNZ BA: Barron's: MYNZ MS: Morningstar: XNAS: MYNZ

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Mainz Biomed N.V.

Mainz Biomed N.V. develops and sells in-vitro diagnostic (IVD) tests for the early detection of cancer in the United States and Europe. It offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. The company also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. In addition, it operates a clinical diagnostic laboratory; and distributes its IVD kits to third-party laboratories. The company has a collaboration agreement with Thermo Fisher Scientific Inc. for the development and commercialization of colorectal cancer screening product. Mainz Biomed N.V. was founded in 2008 and is based in Mainz, Germany.

Similar Companies

Industry: Diagnostics & Research (Germany)

Name	Market Cap (USD) diff.	PE	Country
Centogene N.V. OTCMKTS: CNTGF	$2.09M -63%	-	Germany

Industry: Diagnostics & Research (Global)

Name	Market Cap (USD) diff.	PE	Country
Quest Diagnostics Inc. NYSE: DGX	$20.96B 366K%	20.9	United States
Exact Sciences Corp. NASDAQ: EXAS	$20.03B 350K%	-	United States
Q Qiagen N.V. FRA: QIA	$8.5B 7.3B EUR 149K%	20.2	Netherlands
Chrome Holding Co. OTCMKTS: MEHCQ	$96.4M 2K%	-	United States
Global Cord Blood Corp. OTCMKTS: CORBF	$73.65M 1K%	0.8	Hong Kong
DNA Chip Research Inc. TSE: 2397	$46.18M 7.39B JPY 708%	-	Japan

chevron_leftBack